• 2016

    1) Chan, C. K., Holroyd, C. R., Mason, A., Zarroug, J. and Edwards, C. J. (2016). “Are there dangers in biologic dose reduction strategies?” Autoimmunity Reviews 15(7): 742-746.

    2) Fong, W., Holroyd, C., Davidson, B., Armstrong, R., Harvey, N., Dennison, E., et al. (2016). “The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.” Rheumatology 55(10): 1837-1842.

    3) Holroyd, C. R., Osmond, C., Barker, D. J., Ring, S. M., Lawlor, D. A., Tobias, J. H., et al. (2016). “Placental Size Is Associated Differentially With Postnatal Bone Size and Density.” Journal of Bone & Mineral Research 31(10): 1855-1864.

    4) Sammut, L., Wallis, D. and Holroyd, C. (2016). “Progressive multifocal leukoencephalopathy associated with infliximab.” Journal of the Royal College of Physicians of Edinburgh 46(3): 163-165.

    2015

    1) Marks, J. L., Holroyd, C. R., Dimitrov, B. D., Armstrong, R. D., Calogeras, A., Cooper, C., et al. (2015). “Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy?” Arthritis Care Res (Hoboken) 67(6): 746-753.

    2014

    1) Harvey, N. C., Holroyd, C., Ntani, G., Javaid, K., Cooper, P., Moon, R., et al. (2014). “Vitamin D supplementation in pregnancy: a systematic review.” Health Technology Assessment (Winchester, England) 18(45): 1-190.

     

    2012

     

    1) Holroyd, C., Harvey, N., Dennison, E. and Cooper, C. (2012). “Epigenetic influences in the developmental origins of osteoporosis.” Osteoporos.Int. 23: 401-410.

    2) Holroyd, C. R., Harvey, N. C., Crozier, S. R., Winder, N. R., Mahon, P. A., Ntani, G., et al. (2012). “Placental size at 19 weeks predicts offspring bone mass at birth: Findings from the Southampton Women’s Survey.” Placenta 33: 623-629.

     

    2011

     

    1) Cooper, C., Cole, Z. A., Holroyd, C. R., Earl, S. C., Harvey, N. C., Dennison, E. M., et al. (2011). “Secular trends in the incidence of hip and other osteoporotic fractures.” Osteoporos.Int 22: 1277-1288.

    2) Holroyd, C. R., Cooper, C. and Harvey, N. C. (2011). “Vitamin D and the postmenopausal population.” Menopause.Int. 17: 102-107.

    3) Holroyd, C. R. and Harvey, N. C. (2011). “Bone unfriendly drugs.” Osteoporosis Review 19(3): 1-6.

     

    2010

     

    1) Earl, S., Cole, Z. A., Holroyd, C., Cooper, C. and Harvey, N. C. (2010). “Session 2: Other diseases: Dietary management of osteoporosis throughout the life course.” Proc.Nutr.Soc. 69: 25-33.

    2) Holroyd, C. R., Davies, J. H., Taylor, P., Jameson, K., Rivett, C., Cooper, C., et al. (2010). “Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome.” Osteoporos.Int 21: 2093-2099.

     

    2008

     

    1) Holroyd, C., Cooper, C. and Dennison, E. (2008). “Epidemiology of osteoporosis.” Best.Pract.Res.Clin.Endocrinol Metab 22: 671-685.